{"analyses":[{"ciLowerLimit":"4.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.0","estimateComment":"Difference in percentages based on Miettinen \\& Nurminen method stratified by IMDC risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in percentages","paramValue":"11.0"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.0","upperLimit":"75.7","value":"71.5"},{"groupId":"OG001","lowerLimit":"55.8","upperLimit":"65.3","value":"60.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"432"},{"groupId":"OG001","value":"429"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions), Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), or Stable Disease (SD) per RECIST 1.1 for ≥6 months. The DCR was calculated using the Miettinen \\& Nurminen method stratified by International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World). The percentage of participants who experienced a CR, PR, or SD is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.","id":"OG000","title":"Pembrolizumab + Axitinib"},{"description":"Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.","id":"OG001","title":"Sunitinib"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all randomized participants who experienced a PR, CR or SD for ≥6 months.","reportingStatus":"POSTED","timeFrame":"Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)","title":"Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}